Skip to main content

Advertisement

Log in

Hepatocellular carcinoma

Genome-scale metabolic models for hepatocellular carcinoma

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

A new study proposes a modelling strategy to identify reactions, genes and metabolites relevant in hepatocellular carcinoma using in silico and in vivo analyses. The proposed genome-scale metabolic model integrates genomic and proteomic information, and points to statins, among others, as potential chemopreventive and anticancer drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).

  2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  Google Scholar 

  3. Agren, R. et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol. 10, 721 (2014).

    Article  Google Scholar 

  4. Notarnicola, M., Tutino, V. & Caruso, M. G. Tumor-induced alterations in lipid metabolism. Curr. Med. Chem. http://dx.doi.org/10.2174/0929867321666140303122426.

  5. Singh, S., Singh, P. P., Roberts, L. R. & Sanchez, W. Chemopreventive strategies in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 11, 45–54 (2014).

    Article  CAS  Google Scholar 

  6. Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144, 323–332 (2013).

    Article  CAS  Google Scholar 

  7. Tsan, Y. T. et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Clin. Oncol. 31, 1514–1521 (2013).

    Article  Google Scholar 

  8. Van der Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10, 671–684 (2011).

    Article  CAS  Google Scholar 

  9. Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385–7392 (2009).

    Article  CAS  Google Scholar 

  10. Mardinoglu, A. et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 3083 (2014).

    Article  Google Scholar 

Download references

Acknowledgements

J.M.L. is supported by grants from the European Commission Framework Programme 7 (Heptromic, proposal number 259744), the US National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK076986), the Samuel Waxman Cancer Research Foundation, the Spanish National Health Institute (SAF-2010-16055) and the Asociación Española para el Estudio del Cáncer.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Josep M. Llovet.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pinyol, R., Llovet, J. Genome-scale metabolic models for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 11, 336–337 (2014). https://doi.org/10.1038/nrgastro.2014.70

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.70

  • Springer Nature Limited

This article is cited by

Navigation